# Chinese biotech firms move up value chain as drug deals evolve beyond licensing: analysts

https://mins.news/en/item/74776

- South China Morning Post, 2026-09-26 01:00 UTC
- Science
- Original: https://www.scmp.com/tech/tech-trends/article/3368781/chinas-biotech-firms-move-value-chain-drug-deals-evolve-beyond-licensing-analysts?utm_source=rss_feed

> Analysts say Chinese biotech dealmaking is moving beyond licensing individual drug candidates as the country shifts from follower to global innovation leader. Beijing-based cancer drug developer InnoCare Pharma said Thursday it signed a strategic research collaboration and licensing agreement with US pharmaceutical giant Eli Lilly that could be worth up to US$3.35 billion.